{"id":"https://openalex.org/W2420145262","doi":"https://doi.org/10.1021/acsmedchemlett.5b00205","title":"Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative Pathogens","display_name":"Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative Pathogens","publication_year":2015,"publication_date":"2015-07-12","ids":{"openalex":"https://openalex.org/W2420145262","doi":"https://doi.org/10.1021/acsmedchemlett.5b00205","mag":"2420145262","pmid":"https://pubmed.ncbi.nlm.nih.gov/26288696","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4538447"},"language":"en","primary_location":{"id":"doi:10.1021/acsmedchemlett.5b00205","doi":"https://doi.org/10.1021/acsmedchemlett.5b00205","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acsmedchemlett.5b00205","pdf_url":null,"source":{"id":"https://openalex.org/S191852912","display_name":"ACS Medicinal Chemistry Letters","issn_l":"1948-5875","issn":["1948-5875"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","jufo-1","ki-jl-1","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS Medicinal Chemistry Letters","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4538447/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025449166","display_name":"David C. McKinney","orcid":"https://orcid.org/0000-0003-1787-1841","observed_orcids":["https://orcid.org/0000-0003-1787-1841"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. McKinney","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027471457","display_name":"Gregory S. Basarab","orcid":"https://orcid.org/0000-0001-5684-6046","observed_orcids":["https://orcid.org/0000-0001-5684-6046"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory S. Basarab","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058456108","display_name":"Alexis\u00a0I. Cocozaki","orcid":"https://orcid.org/0000-0002-3547-552X","observed_orcids":["https://orcid.org/0000-0002-3547-552X"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexis I. Cocozaki","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021804052","display_name":"Melinda A. Foulk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melinda A. Foulk","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011696439","display_name":"M.D. Miller","orcid":"https://orcid.org/0000-0001-6543-1918","observed_orcids":["https://orcid.org/0000-0001-6543-1918"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew D. Miller","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088584178","display_name":"Anatoly M. Ruvinsky","orcid":"https://orcid.org/0000-0002-8979-7559","observed_orcids":["https://orcid.org/0000-0002-8979-7559"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anatoly M. Ruvinsky","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083362664","display_name":"Clay W. Scott","orcid":"https://orcid.org/0000-0002-5599-5848","observed_orcids":["https://orcid.org/0000-0002-5599-5848"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Clay W Scott","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057159661","display_name":"Kumar D. Thakur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kumar Thakur","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045889044","display_name":"Liang Zhao","orcid":"https://orcid.org/0000-0001-9244-3121","observed_orcids":["https://orcid.org/0000-0001-9244-3121","https://orcid.org/0000-0002-0257-9082"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liang Zhao","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112785864","display_name":"Ed T. Buurman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ed T. Buurman","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109180462","display_name":"Sridhar Narayan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sridhar Narayan","raw_affiliation_strings":["Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of \u2020Chemistry and \u2021Bioscience, Infection Innovative Medicines; \u00a7Structure and Biophysics, Discovery Sciences; \u2225Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5109180462"],"corresponding_institution_ids":["https://openalex.org/I4210150756"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.6474,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.60060541,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"6","issue":"8","first_page":"930","last_page":"935"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10252","display_name":"Microbial Natural Products and Biosynthesis","score":0.6845999956130981,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10252","display_name":"Microbial Natural Products and Biosynthesis","score":0.6845999956130981,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10521","display_name":"RNA and protein synthesis mechanisms","score":0.1509000062942505,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11103","display_name":"Antimicrobial Peptides and Activities","score":0.0697999969124794,"subfield":{"id":"https://openalex.org/subfields/2404","display_name":"Microbiology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/negamycin","display_name":"negamycin","score":1.0},{"id":"https://openalex.org/keywords/gram-negative-bacteria","display_name":"Gram-negative bacteria","score":0.7879999876022339},{"id":"https://openalex.org/keywords/antibacterial-activity","display_name":"antibacterial activity","score":0.8610000014305115},{"id":"https://openalex.org/keywords/ribosome-binding-site","display_name":"ribosome binding site","score":0.6570000052452087},{"id":"https://openalex.org/keywords/protein-synthesis-inhibition","display_name":"protein synthesis inhibition","score":0.8410000205039978},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.8270000219345093},{"id":"https://openalex.org/keywords/natural-product-derivatives","display_name":"natural product derivatives","score":0.4429999887943268}],"concepts":[{"id":"https://openalex.org/C4937899","wikidata":"https://www.wikidata.org/wiki/Q68541106","display_name":"Antimicrobial","level":2,"score":0.7825367450714111},{"id":"https://openalex.org/C2780104969","wikidata":"https://www.wikidata.org/wiki/Q4774530","display_name":"Antibacterial activity","level":3,"score":0.6014077067375183},{"id":"https://openalex.org/C2779396153","wikidata":"https://www.wikidata.org/wiki/Q901227","display_name":"Natural product","level":2,"score":0.5476832985877991},{"id":"https://openalex.org/C2777752112","wikidata":"https://www.wikidata.org/wiki/Q903238","display_name":"Lead compound","level":3,"score":0.546208918094635},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.45812568068504333},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4485262930393219},{"id":"https://openalex.org/C193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","level":3,"score":0.4238571524620056},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.37790828943252563},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.36333250999450684},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.3566249907016754},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.34859317541122437},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.32819437980651855},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.3176511526107788},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.30308258533477783},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08057302236557007}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1021/acsmedchemlett.5b00205","doi":"https://doi.org/10.1021/acsmedchemlett.5b00205","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acsmedchemlett.5b00205","pdf_url":null,"source":{"id":"https://openalex.org/S191852912","display_name":"ACS Medicinal Chemistry Letters","issn_l":"1948-5875","issn":["1948-5875"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","jufo-1","ki-jl-1","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS Medicinal Chemistry Letters","raw_type":"journal-article"},{"id":"pmid:26288696","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26288696","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS medicinal chemistry letters","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4538447","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4538447/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS Med Chem Lett","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:4538447","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4538447/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS Med Chem Lett","raw_type":"Text"},"sustainable_development_goals":[{"score":0.8048999905586243,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320324860","display_name":"Pharmaron","ror":"https://ror.org/012qm0r35"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W258250165","https://openalex.org/W1901312711","https://openalex.org/W1964509770","https://openalex.org/W1984086638","https://openalex.org/W1990583931","https://openalex.org/W1992271494","https://openalex.org/W2005480696","https://openalex.org/W2014845739","https://openalex.org/W2033184553","https://openalex.org/W2036199133","https://openalex.org/W2039219696","https://openalex.org/W2051168890","https://openalex.org/W2062579552","https://openalex.org/W2066453639","https://openalex.org/W2067212901","https://openalex.org/W2067978064","https://openalex.org/W2086223988","https://openalex.org/W2097185772","https://openalex.org/W2099562135","https://openalex.org/W2105794879","https://openalex.org/W2106359046","https://openalex.org/W2133406641","https://openalex.org/W2136971046","https://openalex.org/W2146157756","https://openalex.org/W2146291304","https://openalex.org/W2158732261","https://openalex.org/W2329148016","https://openalex.org/W2625351517","https://openalex.org/W4251761860","https://openalex.org/W4251806203"],"related_works":["https://openalex.org/W7117321010","https://openalex.org/W2062579552","https://openalex.org/W2099562135","https://openalex.org/W1992271494","https://openalex.org/W2800043051","https://openalex.org/W2597546519","https://openalex.org/W1977407276","https://openalex.org/W2755594177","https://openalex.org/W2439170725","https://openalex.org/W4386889930"],"abstract_inverted_index":{"Negamycin":[0],"is":[1],"a":[2,9,100],"natural":[3],"product":[4],"with":[5,33,51],"antibacterial":[6,82,109],"activity":[7,40,83],"against":[8,84],"broad":[10],"range":[11],"of":[12,17,24,43,46,106],"Gram-negative":[13],"pathogens.":[14,87],"Recent":[15],"revelation":[16],"its":[18,52],"ribosomal":[19,54],"binding":[20,55],"site":[21],"and":[22,38,71,97],"mode":[23],"inhibition":[25],"has":[26],"reinvigorated":[27],"efforts":[28],"to":[29,73,95],"identify":[30],"improved":[31],"analogues":[32],"clinical":[34,104],"potential.":[35],"Translation-inhibitory":[36],"potency":[37],"antimicrobial":[39],"upon":[41],"modification":[42],"different":[44],"moieties":[45],"negamycin":[47,93],"were":[48,69],"in":[49,81],"line":[50],"observed":[53],"conformation,":[56],"reaffirming":[57],"stringent":[58],"structural":[59],"requirements":[60],"for":[61],"activity.":[62],"However,":[63],"substitutions":[64],"on":[65],"the":[66,90],"N6":[67],"amine":[68],"tolerated":[70],"led":[72],"N6-(3-aminopropyl)-negamycin":[74],"(31f),":[75],"an":[76],"analogue":[77],"showing":[78],"4-fold":[79],"improvement":[80],"key":[85],"bacterial":[86],"This":[88],"represents":[89],"most":[91],"potent":[92],"derivative":[94],"date":[96],"may":[98],"be":[99],"stepping":[101],"stone":[102],"toward":[103],"development":[105],"this":[107],"novel":[108],"class.":[110]},"counts_by_year":[{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}